Shibani Malhotra

In a report published Thursday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), and raised the price target from $126.00 to $130.00. In the report, Sterne Agee noted, “We reiterate our Buy thesis on SLXP in front of the FDA panel vote,...

In a report published Tuesday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), and raised the price target from $126.00 to $130.00. In the report, Sterne Agee noted, “The upcoming FDA Advisory Committee on Relistor (scheduled for June 11-...

In a report published Thursday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating on Actavis PLC (NYSE: ACT), and raised the price target from $230.00 to $250.00. In the report, Sterne Agee noted, “We have reevaluated our assumptions regarding the timing and magnitude of the synergies...

In a report published Wednesday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating and $185.00 price target on Allergan (NYSE: AGN). In the report, Sterne Agee noted, “We met with Allergan management today and we have also received feedback from shareholders who spent time with CEO...

In a report published Friday, Sterne Agee analyst Shibani Malhotra reiterated a Neutral rating and $53.00 price target on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). In the report, Sterne Agee noted, “Teva reported 1Q14 earnings this morning of $1.22 (9% increase YoY) on revenues of $5bn (2...

In a report published Thursday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating and $66.00 price target on Endo International PLC (NASDAQ: ENDP). In the report, Sterne Agee noted, “We recommend buying ENDP post the company's announcement that it has settled the majority of its AMS-...

In a report published Tuesday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating and $142.00 price target on Allergan (NYSE: AGN). In the report, Sterne Agee noted, “We believe that Allergan will likely do all it can to resist a hostile takeover by Valeant. The company, however, has now...

Shares of Actavis (NYSE: ACT) are up 2.3 percent to $198.42 in Wednesday's trading after Sterne Agee initiated coverage on the stock with a Buy rating and $230 price target. Analyst Shibani Malhotra sees upside “to the company's pro-revenue and synergy targets, and expects management to continue...

On Wednesday, Sterne Agee initiated coverage on shares of Teva Pharmaceutical Industries (NYSE: TEVA) with a Neutral rating and $53 price target. Analyst Shibani Malhotra believes “strong conversion of Copaxone 20mg/ml to its 40mg/ml formulation is crucial.” The analyst credits the stocks year-to...